Mabtas 100mg

Mabtas is a generic version of Rituximab, a medication used to treat certain types of cancer, including:

• Non-Hodgkin’s lymphoma (NHL)
• Chronic lymphocytic leukemia (CLL)
• Rheumatoid arthritis (RA)

Composition:

Mabtas is a single-ingredient product containing Rituximab, a monoclonal antibody that targets the CD20 antigen on the surface of B cells.

Mechanism of Action:

Rituximab works by binding to the CD20 antigen on the surface of B cells, leading to the activation of complement-mediated cytotoxicity and antibody-dependent cellular cytotoxicity. This results in the destruction of B cells and the inhibition of their growth.

Uses:

Mabtas is used to treat:

• Non-Hodgkin’s lymphoma (NHL)
• Chronic lymphocytic leukemia (CLL)
• Rheumatoid arthritis (RA)

Dosage:

The recommended dosage of Mabtas is:

• 100mg administered as an intravenous infusion
• For NHL and CLL, treatment is typically repeated every 4 weeks for 2-6 cycles
• For RA, treatment is typically administered every 2 months

Side Effects:

Common side effects of Mabtas include:

• Infusion reactions (e.g. fever, chills, rash)
• Infections (e.g. upper respiratory tract infections, urinary tract infections)
• Low white blood cell count
• Low platelet count
• Fatigue
• Nausea and vomiting
• Headache
• Muscle and joint pain
• Skin rash

Recommendation:

Mabtas is recommended for patients with NHL, CLL, or RA who have not responded to previous treatments. Patients should also be advised to monitor their blood counts and liver function regularly during treatment.

Important Note:

Patients should not take Mabtas if they have a history of severe allergic reactions or have had a serious infusion reaction to Rituximab in the past. Patients should also inform their healthcare provider if they have any underlying medical conditions, such as kidney problems or liver problems, before taking Mabtas.

Please note that Mabtas is a generic version of Rituximab and may be available in different countries under different brand names. As with any medication, patients should consult with their healthcare provider to determine the appropriate dosage and treatment schedule.

It’s worth noting that Mabtas is a biological response modifier medication and should only be used under the supervision of a qualified healthcare professional.